|
Concordance of intrinsic subtyping and risk of recurrence (ROR) scores between matched primary and metastatic tissue from Triple Negative Breast Cancer Trial (TNT). |
| |
|
Patents, Royalties, Other Intellectual Property - Co-inventor for the PAM50 bioclassifier for intrinsic subtypes. Uncompensated |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Amgen; AstraZeneca; GlaxoSmithKline; Roche Pharma AG |
| |
|
No Relationships to Disclose |
| |
Andrew Nicholas James Tutt |
No Relationships to Disclose |